Saturday, 10 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

ARAMIS GROUP Stock Is 29% Up In The Last 21 Sessions

Loading stream...

(vianews) - shares of aramis group (cac 40: arami.pa) rose by a staggering 29.76% in 21 sessions from €4.1 to €5.32 at 20:37 est on monday, after two successive sessions in a row of gains. cac 40 is dropping 0.21% to €7,303.81, following the last session's upward trend.

about aramis group

aramis group sas engages in the online sale of used cars in europe. the company operates aramisauto, cardoen, and clicars brands in france, belgium, and spain, as well as carsupermarket platform in the united kingdom. aramis group sas was founded in 2001 and is based in arcueil, france.

earnings per share

as for profitability, aramis group has a trailing twelve months eps of €-0.8.

volume

today's last reported volume for aramis group is 126791 which is 3.79% above its average volume of 91343.

more news about aramis group (arami.pa).

Categories

stockMarket

Tags

Stock PriceMarket Session NowStock Market NowPrice UpMarket SessionStock Price UpStock MarketARAMIS GROUPStockARAMI.PA
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com